AUS
NZ
UK
CA
USA
IND
Highlights
- EBOS Group reported AUD 13.19 billion in total revenue for FY24, a 7.8% YoY increase from FY23.
- In FY24, underlying EBITDA grew by 7.3% to AUD 624.3 million, while underlying NPAT increased by 7.7% to AUD 303.4 million.
- EBOS reaffirmed its FY25 underlying EBITDA guidance of AUD 575 - 600 million.
EBOS Group Limited (ASX:EBO), an ASX-listed marketer, wholesaler, and distributor of healthcare, medical, and pharmaceutical products in Australasia, has reported a decent financial performance for the full year ended 30 June 2024 (FY24). The company achieved a record-breaking total revenue of AUD 13.19 billion in FY24, reflecting a 7.8% YoY growth from AUD 12.24 billion in FY23.
Underlying earnings also showed a steady increase, with EBITDA rising by 7.3% YoY to AUD 624.3 million, while underlying net profit after tax (NPAT) grew 7.7% YoY to AUD 303.4 million.
Positive Outlook for FY25
EBOS Group remains optimistic about its future, reaffirming its FY25 underlying EBITDA guidance of AUD 575 million to AUD 600 million. For the three months ending 30 September 2024, the company recorded a 7.4% YoY increase in underlying EBITDA.
Strategic priorities for the upcoming year include:
- Expanding the TWC network and acquiring new wholesale customers.
- Enhancing operational efficiencies and investing in medical technology and specialist medicines across Australia, New Zealand, and Southeast Asia.
- Implementing a cost reduction program, targeting AUD 25-50 million in savings over the next 1-2 years to counter rising operational costs.
- Pursuing mergers and acquisitions to diversify revenue streams and strengthen its presence in the Community Pharmacy sector.
Leadership Expansion in Animal Care
In a key leadership move, EBOS has appointed Mr. Grant Viney as CEO of EBOS Animal Care, effective 1 February 2025. Mr. Viney, who has been Executive General Manager of EBOS-owned Masterpet since 2019, has played a vital role in growing brands like Black Hawk and Vitapet.
Share performance of EBO
EBO shares closed 0.79% higher at AUD 34.60 per share on 29 January 2025. In one year, EBO’s share price has dropped by almost 0.63%, and in the last three months, it has increased by 2.67%.
52-week high of EBO is AUD 35.31, recorded on 20 February 2024 and 52-week low is AUD 28.75, recorded o 18 June 2024.
Note 1: Past performance is neither an Indicator nor a guarantee of future performance.
Note 2: The reference date for all price data, and currency, is 29 January 2025. The reference data in this report has been partly sourced from EODHD/Others.
Disclaimer
This article has been prepared by Kalkine Media, echoed on the website kalkinemedia.com/au and associated pages, based on the information obtained and collated from the subscription reports prepared by Kalkine Pty. Ltd. [ABN 34 154 808 312; AFSL no. 425376] on Kalkine.com.au (and associated pages). The principal purpose of the content is to provide factual information only for educational purposes. None of the content in this article, including any news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations, and video is or is intended to be, advisory in nature. The content does not contain or imply any recommendation or opinion intended to influence your financial decisions, including but not limited to, in respect of any particular security, transaction, or investment strategy, and must not be relied upon by you as such. The content is provided without any express or implied warranties of any kind. Kalkine Media, and its related bodies corporate, agents, and employees (Kalkine Group) cannot and do not warrant the accuracy, completeness, timeliness, merchantability, or fitness for a particular purpose of the content or the website, and to the extent permitted by law, Kalkine Group hereby disclaims any and all such express or implied warranties. Kalkine Group shall NOT be held liable for any investment or trading losses you may incur by using the information shared on our website.
